SC-435
Based on 1 Customer Validation
SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.14%
- CAS 番号: 289037-67-8
- 分子式: C37H59N3O7S2
- 分子量:722.01
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Bile acid transporter[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Streptozotocin (HY-13753) or Azoxymethane (HY-111375) treated male C57BL/6J mice (25-30 g)[2]
-
Dosage:10 μg/1 g, 16 weeks;
10 μg/1 g, 5 days -
Administration:Oral administration (p.o.)
-
Result:Reduced bile acids and ammonia concentrations in the blood and brain.
Alleviated liver and brain damages.
-
Animal Model:Hartley guinea pigs (250-300 g) with endogenous hypercholesterolemia[3]
-
Dosage:0.1 g/100 g SC-435;
0.03 g/100 g SC-435 combined with 0.05 g/100 g Simvastatin (HY-17502) -
Administration:Oral administration (p.o.); 12 weeks
-
Result:Compared to the control group, CETP activity was 34% and 56% lower with SC-435 and the combination of SC-435 and Simvastatin, respectively.
Compared to the control group, Cholesterol 7α-hydroxylase and HMG-CoA reductase activities were increased 2-fold with SC-435 and the combination of SC-435 and Simvastatin, respectively.
Compared to the control group, HMG-CoA reductase mRNA expression was increased 33% with SC-435.
化学情報
-
CAS 番号 289037-67-8
-
性状 Solid
-
分子量 722.01
-
分子式 C37H59N3O7S2
-
Color White to off-white
-
SMILES
CS(=O)([O-])=O.O[C@@H]1[C@@](C2=CC=C(C=C2)OCCCC[N+]34CCN(CC4)CC3)([H])C5=CC(N(C)C)=CC=C5S(=O)(CC1(CCCC)CCCC)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
DMSO : ≥ 50 mg/mL (69.25 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. West KL, et, al. 1-[4-[4[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]butyl]-4-aza-1-azoniabicyclo[2.2.2]octane methanesulfonate (SC-435), an ileal apical sodium-codependent bile acid transporter inhibitor alters hepatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations in guinea pigs. J Pharmacol Exp Ther. 2002 Oct;303(1):293-9. [Content Brief]
[2]. Xie G, et al. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure. EBioMedicine. 2018 Nov;37:294-306. [Content Brief]
[3]. West KL, et al. SC-435, an ileal apical sodium-codependent bile acid transporter inhibitor alters mRNA levels and enzyme activities of selected genes involved in hepatic cholesterol and lipoprotein metabolism in guinea pigs. J Nutr Biochem. 2005 Dec;16(12):722-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3850 mL | 6.9251 mL | 13.8502 mL | 34.6256 mL |
| 5 mM | 0.2770 mL | 1.3850 mL | 2.7700 mL | 6.9251 mL | |
| 10 mM | 0.1385 mL | 0.6925 mL | 1.3850 mL | 3.4626 mL | |
| 15 mM | 0.0923 mL | 0.4617 mL | 0.9233 mL | 2.3084 mL | |
| 20 mM | 0.0693 mL | 0.3463 mL | 0.6925 mL | 1.7313 mL | |
| 25 mM | 0.0554 mL | 0.2770 mL | 0.5540 mL | 1.3850 mL | |
| 30 mM | 0.0462 mL | 0.2308 mL | 0.4617 mL | 1.1542 mL | |
| 40 mM | 0.0346 mL | 0.1731 mL | 0.3463 mL | 0.8656 mL | |
| 50 mM | 0.0277 mL | 0.1385 mL | 0.2770 mL | 0.6925 mL | |
| 60 mM | 0.0231 mL | 0.1154 mL | 0.2308 mL | 0.5771 mL |
SC-435 関連分類
HY-129982 関連分類
Powered by Bioz